메뉴 건너뛰기




Volumn 270, Issue 3, 2011, Pages 197-205

Chemotherapy only for localized Hodgkin lymphoma

Author keywords

Chemotherapy; Localized hodgkin lymphoma

Indexed keywords

BLEOMYCIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; PREDNISONE; PROCARBAZINE; VINCRISTINE;

EID: 80051561623     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/j.1365-2796.2011.02410.x     Document Type: Review
Times cited : (9)

References (60)
  • 1
    • 33751268711 scopus 로고    scopus 로고
    • Long-term events in adult patients with clinical stage IA-IIA nonbulky Hodgkin's lymphoma treated with four cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine and adjuvant radiotherapy: a single-institution 15-year follow-up
    • Brusamolino E, Baio A, Orlandi E et al. Long-term events in adult patients with clinical stage IA-IIA nonbulky Hodgkin's lymphoma treated with four cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine and adjuvant radiotherapy: a single-institution 15-year follow-up. Clin Cancer Res 2006; 12: 6487-93.
    • (2006) Clin Cancer Res , vol.12 , pp. 6487-6493
    • Brusamolino, E.1    Baio, A.2    Orlandi, E.3
  • 2
    • 33947532554 scopus 로고    scopus 로고
    • Fertility among female hodgkin lymphoma survivors attempting pregnancy following ABVD chemotherapy
    • Hodgson DC, Pintilie M, Gitterman L et al. Fertility among female hodgkin lymphoma survivors attempting pregnancy following ABVD chemotherapy. Hematol Oncol 2007; 25: 11-5.
    • (2007) Hematol Oncol , vol.25 , pp. 11-15
    • Hodgson, D.C.1    Pintilie, M.2    Gitterman, L.3
  • 3
    • 0037102360 scopus 로고    scopus 로고
    • Second malignant neoplasms among long-term survivors of Hodgkin's disease: a population-based evaluation over 25years
    • Dores GM, Metayer C, Curtis RE et al. Second malignant neoplasms among long-term survivors of Hodgkin's disease: a population-based evaluation over 25years. J Clin Oncol 2002; 20: 3484-94.
    • (2002) J Clin Oncol , vol.20 , pp. 3484-3494
    • Dores, G.M.1    Metayer, C.2    Curtis, R.E.3
  • 4
    • 0034128929 scopus 로고    scopus 로고
    • Second malignant neoplasms after treatment for Hodgkin's disease in childhood or adolescence
    • Green DM, Hyland A, Barcos MP et al. Second malignant neoplasms after treatment for Hodgkin's disease in childhood or adolescence. J Clin Oncol 2000; 18: 1492-9.
    • (2000) J Clin Oncol , vol.18 , pp. 1492-1499
    • Green, D.M.1    Hyland, A.2    Barcos, M.P.3
  • 5
    • 0037028736 scopus 로고    scopus 로고
    • Lung cancer following chemotherapy and radiotherapy for Hodgkin's disease
    • Travis LB, Gospodarowicz M, Curtis RE et al. Lung cancer following chemotherapy and radiotherapy for Hodgkin's disease. J Natl Cancer Inst 2002; 94: 182-92.
    • (2002) J Natl Cancer Inst , vol.94 , pp. 182-192
    • Travis, L.B.1    Gospodarowicz, M.2    Curtis, R.E.3
  • 7
    • 33749599695 scopus 로고    scopus 로고
    • Childhood Cancer Survivor S. Chronic health conditions in adult survivors of childhood cancer
    • Oeffinger KC, Mertens AC, Sklar CA et al. Childhood Cancer Survivor S. Chronic health conditions in adult survivors of childhood cancer. N Engl J Med 2006; 355: 1572-82.
    • (2006) N Engl J Med , vol.355 , pp. 1572-1582
    • Oeffinger, K.C.1    Mertens, A.C.2    Sklar, C.A.3
  • 8
    • 0344667638 scopus 로고    scopus 로고
    • Valvular dysfunction and carotid, subclavian, and coronary artery disease in survivors of hodgkin lymphoma treated with radiation therapy
    • Hull MC, Morris CG, Pepine CJ, Mendenhall NP. Valvular dysfunction and carotid, subclavian, and coronary artery disease in survivors of hodgkin lymphoma treated with radiation therapy. JAMA 2003; 290: 2831-7.
    • (2003) JAMA , vol.290 , pp. 2831-2837
    • Hull, M.C.1    Morris, C.G.2    Pepine, C.J.3    Mendenhall, N.P.4
  • 9
    • 0027386156 scopus 로고
    • Factors affecting late mortality from heart disease after treatment of Hodgkin's disease
    • Hancock SL, Tucker MA, Hoppe RT. Factors affecting late mortality from heart disease after treatment of Hodgkin's disease. JAMA 1993; 270: 1949-55.
    • (1993) JAMA , vol.270 , pp. 1949-1955
    • Hancock, S.L.1    Tucker, M.A.2    Hoppe, R.T.3
  • 10
    • 4143078308 scopus 로고    scopus 로고
    • Cardiovascular status in long-term survivors of Hodgkin's disease treated with chest radiotherapy
    • Adams MJ, Lipsitz SR, Colan SD et al. Cardiovascular status in long-term survivors of Hodgkin's disease treated with chest radiotherapy. J Clin Oncol 2004; 22: 3139-48.
    • (2004) J Clin Oncol , vol.22 , pp. 3139-3148
    • Adams, M.J.1    Lipsitz, S.R.2    Colan, S.D.3
  • 11
    • 33847348995 scopus 로고    scopus 로고
    • Late cardiotoxicity after treatment for Hodgkin lymphoma
    • Aleman BM, van den Belt-Dusebout AW, De Bruin ML et al. Late cardiotoxicity after treatment for Hodgkin lymphoma. Blood 2007; 109: 1878-86.
    • (2007) Blood , vol.109 , pp. 1878-1886
    • Aleman, B.M.1    van den Belt-Dusebout, A.W.2    De Bruin, M.L.3
  • 13
    • 1342308406 scopus 로고    scopus 로고
    • Radiation-induced brachial plexopathy: review. Complication without a cure
    • Schierle C, Winograd JM. Radiation-induced brachial plexopathy: review. Complication without a cure. J Reconstr Microsurg 2004; 20: 149-52.
    • (2004) J Reconstr Microsurg , vol.20 , pp. 149-152
    • Schierle, C.1    Winograd, J.M.2
  • 14
    • 77956422190 scopus 로고    scopus 로고
    • Late mortality and morbidity of patients with Hodgkin lymphoma treated in adulthood
    • 2009 ASCO Ann Meeting Proc) Part I 445s (abstract 8547).
    • Matasar MJ, McCallen LN, Reidel ER, Ford JS, Oeffinger KS, Straus D. Late mortality and morbidity of patients with Hodgkin lymphoma treated in adulthood. J Clin Oncol (2009 ASCO Ann Meeting Proc) 2009;27 (Suppl) Part I 445s (abstract 8547).
    • (2009) J Clin Oncol , vol.27 , Issue.SUPPL.
    • Matasar, M.J.1    McCallen, L.N.2    Reidel, E.R.3    Ford, J.S.4    Oeffinger, K.S.5    Straus, D.6
  • 15
    • 70349310318 scopus 로고    scopus 로고
    • Breast cancer risk in female survivors of Hodgkin's lymphoma: lower risk after smaller radiation volumes
    • De Bruin ML, Sparidans J, van't Veer MB et al. Breast cancer risk in female survivors of Hodgkin's lymphoma: lower risk after smaller radiation volumes. J Clin Oncol 2009; 27: 4239-46.
    • (2009) J Clin Oncol , vol.27 , pp. 4239-4246
    • De Bruin, M.L.1    Sparidans, J.2    van't Veer, M.B.3
  • 16
    • 35848959692 scopus 로고    scopus 로고
    • Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease
    • Ferme C, Eghbali H, Meerwaldt JH et al. Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease. N Engl J Med 2007; 357: 1916-27.
    • (2007) N Engl J Med , vol.357 , pp. 1916-1927
    • Ferme, C.1    Eghbali, H.2    Meerwaldt, J.H.3
  • 17
    • 0035890435 scopus 로고    scopus 로고
    • Phase III randomized intergroup trial of subtotal lymphoid irradiation versus doxorubicin, vinblastine, and subtotal lymphoid irradiation for stage IA to IIA Hodgkin's disease
    • Press OW, LeBlanc M, Lichter AS et al. Phase III randomized intergroup trial of subtotal lymphoid irradiation versus doxorubicin, vinblastine, and subtotal lymphoid irradiation for stage IA to IIA Hodgkin's disease. J Clin Oncol 2001; 19: 4238-44.
    • (2001) J Clin Oncol , vol.19 , pp. 4238-4244
    • Press, O.W.1    LeBlanc, M.2    Lichter, A.S.3
  • 18
    • 77956643001 scopus 로고    scopus 로고
    • Early-stage Hodgkin's lymphoma
    • Armitage JO. Early-stage Hodgkin's lymphoma. N Engl J Med 2010;363:893.
    • (2010) N Engl J Med , vol.363 , pp. 893
    • Armitage, J.O.1
  • 19
    • 33745982566 scopus 로고    scopus 로고
    • Combined-modality therapy for clinical stage I or II Hodgkin's lymphoma: long-term results of the European Organisation for Research and Treatment of Cancer H7 randomized controlled trials
    • Noordijk EM, Carde P, Dupouy N et al. Combined-modality therapy for clinical stage I or II Hodgkin's lymphoma: long-term results of the European Organisation for Research and Treatment of Cancer H7 randomized controlled trials. J Clin Oncol 2006; 24: 3128-35.
    • (2006) J Clin Oncol , vol.24 , pp. 3128-3135
    • Noordijk, E.M.1    Carde, P.2    Dupouy, N.3
  • 20
    • 34548186696 scopus 로고    scopus 로고
    • Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin's lymphoma: final results of the GHSG HD7 trial
    • Engert A, Franklin J, Eich HT et al. Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin's lymphoma: final results of the GHSG HD7 trial. J Clin Oncol 2007; 25: 3495-502.
    • (2007) J Clin Oncol , vol.25 , pp. 3495-3502
    • Engert, A.1    Franklin, J.2    Eich, H.T.3
  • 21
    • 77956646155 scopus 로고    scopus 로고
    • Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma
    • Engert A, Plutschow A, Eich HT et al. Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma. N Engl J Med 2010; 363: 640-52.
    • (2010) N Engl J Med , vol.363 , pp. 640-652
    • Engert, A.1    Plutschow, A.2    Eich, H.T.3
  • 22
    • 77957945999 scopus 로고    scopus 로고
    • Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD11 trial
    • Eich HT, Diehl V, Görgen H et al. Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD11 trial. J Clin Oncol 2010; 28: 4199-206.
    • (2010) J Clin Oncol , vol.28 , pp. 4199-4206
    • Eich, H.T.1    Diehl, V.2    Görgen, H.3
  • 23
    • 77949887677 scopus 로고    scopus 로고
    • Second malignant neoplasms in survivors of pediatric Hodgkin's lymphoma treated with low-dose radiation and chemotherapy
    • O'Brien MM, Donaldson SS, Balise RR, Whittemore AS, Link MP. Second malignant neoplasms in survivors of pediatric Hodgkin's lymphoma treated with low-dose radiation and chemotherapy. J Clin Oncol 2010; 28: 1232-9.
    • (2010) J Clin Oncol , vol.28 , pp. 1232-1239
    • O'Brien, M.M.1    Donaldson, S.S.2    Balise, R.R.3    Whittemore, A.S.4    Link, M.P.5
  • 24
    • 0026035289 scopus 로고
    • Treatment of advanced-stage massive mediastinal Hodgkin's disease: the case for combined modality treatment
    • Longo DL, Russo A, Duffey PL et al. Treatment of advanced-stage massive mediastinal Hodgkin's disease: the case for combined modality treatment. J Clin Oncol 1991; 9: 227-35.
    • (1991) J Clin Oncol , vol.9 , pp. 227-235
    • Longo, D.L.1    Russo, A.2    Duffey, P.L.3
  • 25
    • 0027154578 scopus 로고
    • Hodgkin's disease with bulky mediastinal involvement: effective management with combined modality therapy
    • Behar RA, Horning SJ, Hoppe RT. Hodgkin's disease with bulky mediastinal involvement: effective management with combined modality therapy. Int J Radiat Oncol Biol Phys 1993; 25: 771-6.
    • (1993) Int J Radiat Oncol Biol Phys , vol.25 , pp. 771-776
    • Behar, R.A.1    Horning, S.J.2    Hoppe, R.T.3
  • 26
    • 77956448858 scopus 로고    scopus 로고
    • FDG-PET guided consolidative radiotherapy in patients with advanced stage Hodgkin lymphoma with residual abnormalites on post chemotherapy CT scan
    • ASH Annual Meeting Abstracts:Abstract 213.
    • Savage KJ, Connors JM, Wilson D et al. FDG-PET guided consolidative radiotherapy in patients with advanced stage Hodgkin lymphoma with residual abnormalites on post chemotherapy CT scan. Blood 2007;110(ASH Annual Meeting Abstracts):Abstract 213.
    • (2007) Blood , vol.110
    • Savage, K.J.1    Connors, J.M.2    Wilson, D.3
  • 27
    • 9444292843 scopus 로고    scopus 로고
    • Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II, and IIIA nonbulky Hodgkin disease
    • Straus DJ, Portlock CS, Qin J et al. Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II, and IIIA nonbulky Hodgkin disease. Blood 2004; 104: 3483-9.
    • (2004) Blood , vol.104 , pp. 3483-3489
    • Straus, D.J.1    Portlock, C.S.2    Qin, J.3
  • 28
    • 23044452477 scopus 로고    scopus 로고
    • Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group
    • Meyer RM, Gospodarowicz MK, Connors JM et al. Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group. J Clin Oncol 2005; 23: 4634-42.
    • (2005) J Clin Oncol , vol.23 , pp. 4634-4642
    • Meyer, R.M.1    Gospodarowicz, M.K.2    Connors, J.M.3
  • 29
    • 33746868428 scopus 로고    scopus 로고
    • Comparison of three radiation dose levels after EBVP regimen in favorable supradiaphragmatic clinical stages (CS) I-II Hodgkin's lymphoma (HL): preliminary results of the EORTC-GELA H9-F trial
    • abstract abstract #814.
    • Eghbali H, Brice P, Creemers G-Y et al. Comparison of three radiation dose levels after EBVP regimen in favorable supradiaphragmatic clinical stages (CS) I-II Hodgkin's lymphoma (HL): preliminary results of the EORTC-GELA H9-F trial. Blood. [abstract]. 2005;106(11):240a, abstract #814.
    • (2005) Blood , vol.106 , Issue.11 , pp. 240
    • Eghbali, H.1    Brice, P.2    Creemers, G.-Y.3
  • 30
    • 0028047202 scopus 로고
    • Preliminary results of the EORTC-GPMC controlled clinical trial H7 in early-stage Hodgkin's disease. EORTC Lymphoma Cooperative Group. Groupe Pierre-et-Marie-Curie
    • Noordijk EM, Carde P, Mandard AM et al. Preliminary results of the EORTC-GPMC controlled clinical trial H7 in early-stage Hodgkin's disease. EORTC Lymphoma Cooperative Group. Groupe Pierre-et-Marie-Curie. Ann Oncol 1994; 5(Suppl 2): 107-12.
    • (1994) Ann Oncol , vol.5 , Issue.SUPPL. 2 , pp. 107-112
    • Noordijk, E.M.1    Carde, P.2    Mandard, A.M.3
  • 31
    • 10944270230 scopus 로고    scopus 로고
    • Treatment of stage I and II Hodgkin's lymphoma with ABVD chemotherapy: results after 7years of a prospective study
    • Rueda Dominguez A, Marquez A, Guma J et al. Treatment of stage I and II Hodgkin's lymphoma with ABVD chemotherapy: results after 7years of a prospective study. Ann Oncol 2004; 15: 1798-804.
    • (2004) Ann Oncol , vol.15 , pp. 1798-1804
    • Rueda Dominguez, A.1    Marquez, A.2    Guma, J.3
  • 32
    • 67849094261 scopus 로고    scopus 로고
    • The addition of radiotherapy to chemotherapy does not improve outcome of early stage Hodgkin's lymphoma patients: a retrospective long-term follow-up analysis of a regional Italian experience
    • Olcese F, Clavio M, Rossi E et al. The addition of radiotherapy to chemotherapy does not improve outcome of early stage Hodgkin's lymphoma patients: a retrospective long-term follow-up analysis of a regional Italian experience. Ann Hematol 2009; 88: 855-61.
    • (2009) Ann Hematol , vol.88 , pp. 855-861
    • Olcese, F.1    Clavio, M.2    Rossi, E.3
  • 33
    • 77951925455 scopus 로고    scopus 로고
    • Treatment of favorable, limited-stage Hodgkin's lymphoma with chemotherapy without consolidation by radiation therapy
    • Canellos GP, Abramson JS, Fisher DC, LaCasce AS. Treatment of favorable, limited-stage Hodgkin's lymphoma with chemotherapy without consolidation by radiation therapy. J Clin Oncol 2010; 28: 1611-5.
    • (2010) J Clin Oncol , vol.28 , pp. 1611-1615
    • Canellos, G.P.1    Abramson, J.S.2    Fisher, D.C.3    LaCasce, A.S.4
  • 34
    • 4344699405 scopus 로고    scopus 로고
    • ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin's disease: long-term results
    • Bonadonna G, Bonfante V, Viviani S, Di Russo A, Villani F, Valagussa P. ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin's disease: long-term results. J Clin Oncol 2004; 22: 2835-41.
    • (2004) J Clin Oncol , vol.22 , pp. 2835-2841
    • Bonadonna, G.1    Bonfante, V.2    Viviani, S.3    Di Russo, A.4    Villani, F.5    Valagussa, P.6
  • 35
    • 32944468191 scopus 로고    scopus 로고
    • Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin's lymphoma
    • Martin WG, Ristow KM, Habermann TM, Colgan JP, Witzig TE, Ansell SM. Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin's lymphoma. J Clin Oncol 2005; 23: 7614-20.
    • (2005) J Clin Oncol , vol.23 , pp. 7614-7620
    • Martin, W.G.1    Ristow, K.M.2    Habermann, T.M.3    Colgan, J.P.4    Witzig, T.E.5    Ansell, S.M.6
  • 36
    • 0034985051 scopus 로고    scopus 로고
    • Secondary prophylactic G-CSF (filgrastim) administration in chemotherapy of stage I and II Hodgkin's lymphoma with ABVD
    • Rueda A, Sevilla I, Guma J et al. Secondary prophylactic G-CSF (filgrastim) administration in chemotherapy of stage I and II Hodgkin's lymphoma with ABVD. Leuk Lymphoma 2001; 4: 353-8.
    • (2001) Leuk Lymphoma , vol.4 , pp. 353-358
    • Rueda, A.1    Sevilla, I.2    Guma, J.3
  • 37
    • 33750510485 scopus 로고    scopus 로고
    • Safety and efficacy of once-per-cycle pegfilgrastim in support of ABVD chemotherapy in patients with Hodgkin lymphoma
    • Younes A, Fayad L, Romaguera J, Pro B, Goy A, Wang M. Safety and efficacy of once-per-cycle pegfilgrastim in support of ABVD chemotherapy in patients with Hodgkin lymphoma. Eur J Cancer 2006; 42: 2976-81.
    • (2006) Eur J Cancer , vol.42 , pp. 2976-2981
    • Younes, A.1    Fayad, L.2    Romaguera, J.3    Pro, B.4    Goy, A.5    Wang, M.6
  • 38
    • 51349157757 scopus 로고    scopus 로고
    • Isolated neutropenia during ABVD chemotherapy for Hodgkin lymphoma does not require growth factor support
    • Nangalia J, Smith H, Wimperis JZ. Isolated neutropenia during ABVD chemotherapy for Hodgkin lymphoma does not require growth factor support. Leuk Lymphoma 2008; 49: 1530-6.
    • (2008) Leuk Lymphoma , vol.49 , pp. 1530-1536
    • Nangalia, J.1    Smith, H.2    Wimperis, J.Z.3
  • 39
    • 34249285155 scopus 로고    scopus 로고
    • G-CSF is not necessary to maintain over 99% dose-intensity with ABVD in the treatment of Hodgkin lymphoma: low toxicity and excellent outcomes in a 10-year analysis
    • Evens AM, Cilley J, Ortiz T et al. G-CSF is not necessary to maintain over 99% dose-intensity with ABVD in the treatment of Hodgkin lymphoma: low toxicity and excellent outcomes in a 10-year analysis. Br J Haematol 2007; 137: 545-52.
    • (2007) Br J Haematol , vol.137 , pp. 545-552
    • Evens, A.M.1    Cilley, J.2    Ortiz, T.3
  • 40
    • 40949131869 scopus 로고    scopus 로고
    • Prophylactic use of filgrastim with ABVD and BEACOPP chemotherapy regimens for Hodgkin lymphoma
    • Wedgwood A, Younes A. Prophylactic use of filgrastim with ABVD and BEACOPP chemotherapy regimens for Hodgkin lymphoma. Clin Lymphoma Myeloma 2007; 8(Suppl 2): S63-6.
    • (2007) Clin Lymphoma Myeloma , vol.8 , Issue.SUPPL. 2
    • Wedgwood, A.1    Younes, A.2
  • 41
    • 0033932803 scopus 로고    scopus 로고
    • Gemcitabine in the treatment of refractory Hodgkin's disease: results of a multicenter phase II study
    • Santoro A, Bredenfeld H, Devizzi L et al. Gemcitabine in the treatment of refractory Hodgkin's disease: results of a multicenter phase II study. J Clin Oncol 2000; 18: 2615-9.
    • (2000) J Clin Oncol , vol.18 , pp. 2615-2619
    • Santoro, A.1    Bredenfeld, H.2    Devizzi, L.3
  • 42
    • 0033782490 scopus 로고    scopus 로고
    • Value of gemcitabine treatment in heavily pretreated Hodgkin's disease patients
    • Zinzani PL, Bendandi M, Stefoni V et al. Value of gemcitabine treatment in heavily pretreated Hodgkin's disease patients. Haematologica 2000; 85: 926-9.
    • (2000) Haematologica , vol.85 , pp. 926-929
    • Zinzani, P.L.1    Bendandi, M.2    Stefoni, V.3
  • 43
    • 34447320514 scopus 로고    scopus 로고
    • Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804
    • Bartlett NL, Niedzwiecki D, Johnson JL et al. Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804. Ann Oncol 2007; 18: 1071-9.
    • (2007) Ann Oncol , vol.18 , pp. 1071-1079
    • Bartlett, N.L.1    Niedzwiecki, D.2    Johnson, J.L.3
  • 44
    • 79956356218 scopus 로고    scopus 로고
    • Doxorubicin, vinblastine, gemcitabine (CALGB 50203) for stage I/II non-bulky Hodgkin lymphoma: pretreatment prognostic factors and interim PET
    • Straus DJ, Johnson JL, Lacasce AS et al. Doxorubicin, vinblastine, gemcitabine (CALGB 50203) for stage I/II non-bulky Hodgkin lymphoma: pretreatment prognostic factors and interim PET. Blood 2011; 117: 5314-20.
    • (2011) Blood , vol.117 , pp. 5314-5320
    • Straus, D.J.1    Johnson, J.L.2    Lacasce, A.S.3
  • 45
    • 0042449063 scopus 로고    scopus 로고
    • Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group
    • Cheson BD, Horning SJ, Coiffier B et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999; 17: 1244.
    • (1999) J Clin Oncol , vol.17 , pp. 1244
    • Cheson, B.D.1    Horning, S.J.2    Coiffier, B.3
  • 46
    • 33947496614 scopus 로고    scopus 로고
    • Revised response criteria for malignant lymphoma
    • International Harmonization Project on L.
    • Cheson BD, Pfistner B, Juweid ME et al., International Harmonization Project on L. Revised response criteria for malignant lymphoma. J Clin Oncol 2007; 25: 579-86.
    • (2007) J Clin Oncol , vol.25 , pp. 579-586
    • Cheson, B.D.1    Pfistner, B.2    Juweid, M.E.3
  • 47
    • 2342453866 scopus 로고    scopus 로고
    • How important is bleomycin in the adriamycin + bleomycin + vinblastine + dacarbazine regimen?
    • Canellos GP, Duggan D, Johnson J, Niedzwiecki D. How important is bleomycin in the adriamycin + bleomycin + vinblastine + dacarbazine regimen? J Clin Oncol 2004; 22: 1532-3.
    • (2004) J Clin Oncol , vol.22 , pp. 1532-1533
    • Canellos, G.P.1    Duggan, D.2    Johnson, J.3    Niedzwiecki, D.4
  • 48
    • 34249949761 scopus 로고    scopus 로고
    • Outcome of patients experiencing progression or relapse after primary treatment with two cycles of chemotherapy and radiotherapy for early-stage favorable Hodgkin's lymphoma
    • Sieniawski M, Franklin J, Nogova L et al. Outcome of patients experiencing progression or relapse after primary treatment with two cycles of chemotherapy and radiotherapy for early-stage favorable Hodgkin's lymphoma. J Clin Oncol 2007; 25: 2000-5.
    • (2007) J Clin Oncol , vol.25 , pp. 2000-2005
    • Sieniawski, M.1    Franklin, J.2    Nogova, L.3
  • 49
    • 19244367762 scopus 로고    scopus 로고
    • Thoracic positron emission tomography using 18F-fluorodeoxyglucose for the evaluation of residual mediastinal Hodgkin disease
    • Weihrauch MR, Re D, Scheidhauer K et al. Thoracic positron emission tomography using 18F-fluorodeoxyglucose for the evaluation of residual mediastinal Hodgkin disease. Blood 2001; 98: 2930-4.
    • (2001) Blood , vol.98 , pp. 2930-2934
    • Weihrauch, M.R.1    Re, D.2    Scheidhauer, K.3
  • 50
    • 33751576028 scopus 로고    scopus 로고
    • FDG-PET after 1 cycle of therapy predicts outcome in diffuse large cell lymphoma and classic Hodgkin disease
    • Kostakoglu L, Goldsmith SJ, Leonard JP et al. FDG-PET after 1 cycle of therapy predicts outcome in diffuse large cell lymphoma and classic Hodgkin disease. Cancer 2006; 107: 2678-87.
    • (2006) Cancer , vol.107 , pp. 2678-2687
    • Kostakoglu, L.1    Goldsmith, S.J.2    Leonard, J.P.3
  • 51
    • 25444437438 scopus 로고    scopus 로고
    • Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphoma
    • Hutchings M, Mikhaeel NG, Fields PA, Nunan T, Timothy AR. Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphoma. Ann Oncol 2005; 16: 1160-8.
    • (2005) Ann Oncol , vol.16 , pp. 1160-1168
    • Hutchings, M.1    Mikhaeel, N.G.2    Fields, P.A.3    Nunan, T.4    Timothy, A.R.5
  • 52
    • 30144432586 scopus 로고    scopus 로고
    • FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma
    • Hutchings M, Loft A, Hansen M et al. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood 2006; 107: 52-9.
    • (2006) Blood , vol.107 , pp. 52-59
    • Hutchings, M.1    Loft, A.2    Hansen, M.3
  • 53
    • 34548486030 scopus 로고    scopus 로고
    • Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study
    • Gallamini A, Hutchings M, Rigacci L et al. Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study. J Clin Oncol 2007; 25: 3746-52.
    • (2007) J Clin Oncol , vol.25 , pp. 3746-3752
    • Gallamini, A.1    Hutchings, M.2    Rigacci, L.3
  • 54
    • 80051561275 scopus 로고    scopus 로고
    • PET-CT adapted therapy after 3 cycles of ABVD for all stages of Hodgkin lymphoma. Interim analysis in 173 patients
    • Pavlovsky S, Pavlovsky A, Fernandez I et al. PET-CT adapted therapy after 3 cycles of ABVD for all stages of Hodgkin lymphoma. Interim analysis in 173 patients. Blood (ASH Annual Meeting Abstracts) 2010; 116: Abstract 1772.
    • (2010) Blood (ASH Annual Meeting Abstracts , vol.116
    • Pavlovsky, S.1    Pavlovsky, A.2    Fernandez, I.3
  • 55
    • 68749112687 scopus 로고    scopus 로고
    • T I. Results of the 2nd planned interim analysis of the RAPID Trial (involved field radiotherapy versus no further treatment) in patients with clinical stages 1A and 2A Hodgkin lymphoma and a 'negative' FDG-PET scan after 3 cycles ABVD
    • ASH Annual Meeting Abstracts :Abstract 369.
    • Radford J, O'Doherty M, Barrington S et al., T I. Results of the 2nd planned interim analysis of the RAPID Trial (involved field radiotherapy versus no further treatment) in patients with clinical stages 1A and 2A Hodgkin lymphoma and a 'negative' FDG-PET scan after 3 cycles ABVD. Blood (ASH Annual Meeting Abstracts) 2008;112:Abstract 369.
    • (2008) Blood , vol.112
    • Radford, J.1    O'Doherty, M.2    Barrington, S.3
  • 56
    • 80051559583 scopus 로고    scopus 로고
    • Results of the 3rd planned interim analysis of the UK NCRI RAPID trial (involved field radiotherapy versus no further treatment) in patients with clinical stages IA/IIA Hodgkin lymphoma and a 'negative' 18-FDG-PET scan after 3 cycles ABVD (Abstract P059)
    • 8th International Symposium on Hodgkin Lymphoma.
    • Radford J, O'Doherty M, Barrington S et al. Results of the 3rd planned interim analysis of the UK NCRI RAPID trial (involved field radiotherapy versus no further treatment) in patients with clinical stages IA/IIA Hodgkin lymphoma and a 'negative' 18-FDG-PET scan after 3 cycles ABVD (Abstract P059). Haematologica (8th International Symposium on Hodgkin Lymphoma) 2010; 95(Suppl. 4): S16-7.
    • (2010) Haematologica , vol.95 , Issue.SUPPL. 4
    • Radford, J.1    O'Doherty, M.2    Barrington, S.3
  • 57
    • 0037567428 scopus 로고    scopus 로고
    • Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease
    • Diehl V, Franklin J, Pfreundschuh M et al. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med 2003; 348: 2386-95.
    • (2003) N Engl J Med , vol.348 , pp. 2386-2395
    • Diehl, V.1    Franklin, J.2    Pfreundschuh, M.3
  • 58
    • 33846863991 scopus 로고    scopus 로고
    • Risk-adapted BEACOPP regimen can reduce the cumulative dose of chemotherapy for standard and high-risk Hodgkin lymphoma with no impairment of outcome
    • Dann EJ, Bar-Shalom R, Tamir A et al. Risk-adapted BEACOPP regimen can reduce the cumulative dose of chemotherapy for standard and high-risk Hodgkin lymphoma with no impairment of outcome. Blood 2007; 109: 905-9.
    • (2007) Blood , vol.109 , pp. 905-909
    • Dann, E.J.1    Bar-Shalom, R.2    Tamir, A.3
  • 59
    • 32044474222 scopus 로고    scopus 로고
    • Natural history of thyroid nodules in survivors of pediatric Hodgkin lymphoma
    • Metzger ML, Howard SC, Hudson MM et al. Natural history of thyroid nodules in survivors of pediatric Hodgkin lymphoma. Pediatr Blood Cancer 2006; 46: 314-9.
    • (2006) Pediatr Blood Cancer , vol.46 , pp. 314-319
    • Metzger, M.L.1    Howard, S.C.2    Hudson, M.M.3
  • 60
    • 27244437759 scopus 로고    scopus 로고
    • Stroke as a late treatment effect of Hodgkin's Disease: a report from the Childhood Cancer Survivor Study
    • Bowers DC, McNeil DE, Liu Y et al. Stroke as a late treatment effect of Hodgkin's Disease: a report from the Childhood Cancer Survivor Study. J Clin Oncol 2005; 27: 6508-15.
    • (2005) J Clin Oncol , vol.27 , pp. 6508-6515
    • Bowers, D.C.1    McNeil, D.E.2    Liu, Y.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.